2025 Gene Therapy On Neurological Diseases Industry Trends Report: Long-Term Outlook Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Gene Therapy On Neurological Diseases Market Size By 2025?
The market size for gene therapy on neurological diseases has seen swift expansion in the past years. The market expects a growth from $3.13 billion in 2024 to $3.55 billion in 2025 with a compound annual growth rate (CAGR) of 13.2%. This significant increase in the earlier period can be attributed to the surge in occurrences of neurological disorders, an upswing in the requirement for personalized medicine, growth in the investing in biotech research and development, a escalation in clinical trial activities, and an increase in authorizations for gene therapies.

How Big Is the Gene Therapy On Neurological Diseases Market Size Expected to Grow by 2029?
The market size of gene therapy for neurological diseases is forecasted to experience significant expansion over the coming years. By 2029, it is predicted to escalate to $5.76 billion, with a Compound Annual Growth Rate (CAGR) of 12.9%. This anticipated growth could be ascribed to several factors spanning from heightened clinical trial activity worldwide to an upward trend in global healthcare infrastructure. Increased awareness about rare diseases, a burgeoning pipeline of gene therapies, and growing strategic alliances and collaborations further fuel this growth. Key trends projected for the forecast period encompass the incorporation of technology in remote patient monitoring, innovative advancements in vector production platforms, application of technology-aided automation in biomanufacturing, the inception of gene therapies catered to extremely rare pediatric Central Nervous System (CNS) disorders, and the introduction of genomic screening in clinical environments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Which Key Market Drivers Powering Gene Therapy On Neurological Diseases Market Expansion and Growth?
The escalating cases of neurological diseases are anticipated to bolster the expansion of the concept of gene therapy dealing with neurological ailments in the market. Neurological disorders encompass medical conditions impacting the brain, spinal cord and nerves, which result in a spectrum of symptoms such as cognitive, motor, and sensory deficits. The surge in the instances of neurological disorders can be attributed to a growing aging population, considering that aging gradually deteriorates neuronal operations, diminishes brain flexibility, and intensifies oxidative stress, all leading to the onset and furthering of these disorders. Gene therapy focusing on neurological diseases helps in managing such disorders by addressing the underlying genetic sources, thus promising potential long-term or even permanent remedies. This enhances patients' prognosis by either restoring or altering gene functionality, lessening symptom severity and decreasing the requirement for regular interventions, thereby improving the overall life quality. For example, data by the National Health Service, a government agency based in the UK, illustrated that there were 487,432 patients identified with dementia (a progressive brain disorder impeding memory, thinking capability, and daily activities) by June 30, 2024. This marked an augmented figure by 3,155 cases compared to May 31, 2024. Thus, the mounting prevalence of neurological disorders is propelling the growth of the market for gene therapy targeting neurological diseases.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

What Trends Will Shape the Gene Therapy On Neurological Diseases Market Through 2029 and Beyond?
Leading companies engaged in the therapeutic market of neurological genetic diseases are channeling their efforts into devising improved viral delivery technologies such as the adeno-associated virus serotype 2 (AAV2) vector. The aim is to enhance precision in gene delivery, boost effectiveness, limit immune reactions, and facilitate enduring treatments. Adeno-associated virus serotype 2 (AAV2) vector is a genetically modified, non-pathogenic viral transport mechanism used in gene therapy to convey curative genes to the targeted cells, specifically neurons, ensuring long-term gene expression. An example is when PTC Therapeutics Inc., an American biopharmaceutical company, got approval from the U.S. Food and Drug Administration (FDA) for a gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency in November 2024. The therapy utilizes an AAV2 vector to transmit a working copy of the DDC gene into the putamen, facilitating the production of dopamine and the enhancement of motor functions. It incorporates a one-time, intraputaminal infusion engineered to offer continuous therapeutic effects, notably enhancing motor function and curbing incapacitating symptoms without necessitating further interventions.

What Are the Emerging Segments in the Gene Therapy On Neurological Diseases Market?
The gene therapy on neurological diseases market covered in this report is segmented

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer's Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications

Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Who Are the Global Leaders in the Gene Therapy On Neurological Diseases Market?
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

Which are the Top Profitable Regional Markets for the Gene Therapy On Neurological Diseases Industry?
North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27294

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.